EE05331B1 - Bensamiididerivaati sisaldav farmatseutiline preparaat - Google Patents

Bensamiididerivaati sisaldav farmatseutiline preparaat

Info

Publication number
EE05331B1
EE05331B1 EEP200200073A EEP200200073A EE05331B1 EE 05331 B1 EE05331 B1 EE 05331B1 EE P200200073 A EEP200200073 A EE P200200073A EE P200200073 A EEP200200073 A EE P200200073A EE 05331 B1 EE05331 B1 EE 05331B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical preparation
preparation containing
benzamide derivative
benzamide
derivative
Prior art date
Application number
EEP200200073A
Other languages
English (en)
Estonian (et)
Inventor
Suzuki Tsuneji
Ando Tomoyuki
Ishibashi Masahiko
Sakabe Masahiro
Sakai Ikuo
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200200073A publication Critical patent/EE200200073A/xx
Publication of EE05331B1 publication Critical patent/EE05331B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200073A 1999-08-16 2000-08-16 Bensamiididerivaati sisaldav farmatseutiline preparaat EE05331B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22955199A JP2001064177A (ja) 1999-08-16 1999-08-16 ベンズアミド誘導体を有効成分とする製剤
PCT/EP2000/008011 WO2001012193A1 (en) 1999-08-16 2000-08-16 Pharmaceutical agent comprising a benzamide derivative as active ingredient

Publications (2)

Publication Number Publication Date
EE200200073A EE200200073A (et) 2003-04-15
EE05331B1 true EE05331B1 (et) 2010-08-16

Family

ID=16893948

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200073A EE05331B1 (et) 1999-08-16 2000-08-16 Bensamiididerivaati sisaldav farmatseutiline preparaat

Country Status (29)

Country Link
EP (1) EP1207881B1 (xx)
JP (2) JP2001064177A (xx)
KR (1) KR100683876B1 (xx)
CN (1) CN1205931C (xx)
AR (1) AR031074A1 (xx)
AU (1) AU780151B2 (xx)
BG (1) BG65662B1 (xx)
BR (1) BR0013283A (xx)
CA (1) CA2380757C (xx)
CY (1) CY1116273T1 (xx)
CZ (1) CZ302924B6 (xx)
DK (1) DK1207881T3 (xx)
EE (1) EE05331B1 (xx)
ES (1) ES2536705T3 (xx)
HK (1) HK1046501B (xx)
HR (1) HRP20020181B1 (xx)
HU (1) HU230386B1 (xx)
IL (1) IL148169A0 (xx)
MX (1) MXPA02001575A (xx)
NO (1) NO328957B1 (xx)
NZ (1) NZ517356A (xx)
PL (1) PL201388B1 (xx)
PT (1) PT1207881E (xx)
RU (1) RU2257206C2 (xx)
SK (1) SK287547B6 (xx)
TW (1) TWI245630B (xx)
UA (1) UA73316C2 (xx)
WO (1) WO2001012193A1 (xx)
ZA (1) ZA200201466B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US20040034039A1 (en) * 2000-09-22 2004-02-19 Yoshinori Nakano Solid preparations
IL163875A0 (en) 2002-03-07 2005-12-18 Univ Delaware Methods, compositions, and kits for enhancing oli gonucleotide mediated nucleic acid sequence alteration using compositions comprising a histone de
GB0316206D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
CA2680838A1 (en) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
KR101405615B1 (ko) * 2007-08-27 2014-06-12 (주)아모레퍼시픽 조성물 내 ｐＨ 조절을 통해 안정화된 벤즈아미드 화합물을함유하는 피부 외용제 조성물, 및 그 벤즈아미드 화합물안정화 방법
ES2378640T3 (es) * 2008-08-29 2012-04-16 Bayer Pharma Aktiengesellschaft Polimorfo B de N-(2-aminofenil)-4-[N-(piridin-3-il)metoxicarbonilaminometil]benzamida (MS-275)
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
TWI645863B (zh) * 2013-04-04 2019-01-01 日商第一三共股份有限公司 胺基羧酸之鹽的固形組成物
WO2016148264A1 (ja) 2015-03-19 2016-09-22 第一三共株式会社 着色剤を含有する固形製剤
WO2016148263A1 (ja) 2015-03-19 2016-09-22 第一三共株式会社 抗酸化剤を含有する固形製剤
WO2020153520A1 (ko) * 2019-01-25 2020-07-30 (주)아모레퍼시픽 벤조산아마이드 화합물 및 용해보조제를 포함하는 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer

Also Published As

Publication number Publication date
CZ302924B6 (cs) 2012-01-18
CA2380757C (en) 2009-01-27
JP4854158B2 (ja) 2012-01-18
HUP0203226A3 (en) 2003-12-29
JP2003507330A (ja) 2003-02-25
WO2001012193A1 (en) 2001-02-22
DK1207881T3 (da) 2015-06-22
HRP20020181A2 (en) 2005-10-31
SK2092002A3 (en) 2002-07-02
AR031074A1 (es) 2003-09-10
CN1370068A (zh) 2002-09-18
SK287547B6 (sk) 2011-01-04
HK1046501B (zh) 2005-09-30
JP2001064177A (ja) 2001-03-13
RU2257206C2 (ru) 2005-07-27
EE200200073A (et) 2003-04-15
CN1205931C (zh) 2005-06-15
UA73316C2 (uk) 2005-07-15
PL201388B1 (pl) 2009-04-30
PT1207881E (pt) 2015-06-05
MXPA02001575A (es) 2003-10-14
BR0013283A (pt) 2002-04-23
AU780151B2 (en) 2005-03-03
ZA200201466B (en) 2002-09-02
EP1207881A1 (en) 2002-05-29
HU230386B1 (hu) 2016-03-29
AU6442700A (en) 2001-03-13
CA2380757A1 (en) 2001-02-22
CY1116273T1 (el) 2017-02-08
RU2002106815A (ru) 2004-01-27
BG106516A (en) 2002-10-31
PL353449A1 (en) 2003-11-17
ES2536705T3 (es) 2015-05-27
NO328957B1 (no) 2010-06-28
NZ517356A (en) 2003-07-25
NO20020774L (no) 2002-03-04
BG65662B1 (bg) 2009-05-29
CZ2002540A3 (cs) 2002-06-12
KR20020020815A (ko) 2002-03-15
KR100683876B1 (ko) 2007-02-15
HK1046501A1 (en) 2003-01-17
IL148169A0 (en) 2002-09-12
HRP20020181B1 (hr) 2016-01-29
EP1207881B1 (en) 2015-04-01
TWI245630B (en) 2005-12-21
NO20020774D0 (no) 2002-02-15
HUP0203226A2 (hu) 2003-01-28

Similar Documents

Publication Publication Date Title
EE05063B1 (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DK1207868T3 (da) Farmaceutiske tramadolsalte
PT984773E (pt) Formulacao farmaceutica a base de omeprazole
ITMI20001450A0 (it) Nuova composizione farmaceutica
NO20005218D0 (no) Farmasøytisk aerosolpreparat
DK1466615T3 (da) Farmaceutisk præparat
NO20015149D0 (no) Nytt farmasöytisk preparat
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
NO20022606L (no) Farmasöytiske kombinasjoner
NO20014926L (no) Farmasöytiske forbindelser
EE05331B1 (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
NO20015148L (no) Nytt farmasöytisk preparat
EE9900545A (et) Farmatseutiline kompositsioon
DK1227817T3 (da) Ciclesonid-holdigt vandigt farmaceutisk præparat
NO20015104D0 (no) Nytt farmasöytisk preparat
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20016430L (no) Farmasöytisk kompleks
NO20015105L (no) Nytt farmasöytisk preparat
NO20021036D0 (no) Farmasöytisk preparat
SE9904819D0 (sv) A new pharmaceutical composition
SE9800251D0 (sv) A novel pharmaceutical preparation
DK1060749T3 (da) Vandigt farmaceutisk præparat indeholdende Tezosentan
DE50008261D1 (de) Retardierte darreichungsform enthaltend tramadolsaccharinat
SE9804128D0 (sv) A new pharmaceutical composition

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner